In the FSGS group, strong CD44 expression III in the mesangium was observed in 5 patients (17%); it was moderate in 15 patients (52%), mild in 7 patients (24%), and absent in 2 patients (7%). This evidence concerns the gene CD44 and focal segmental glomerulosclerosis.